# Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

> **NCT03008278** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (actual)

## Conditions studied

- Metastatic Esophageal Carcinoma
- Metastatic Gastric Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Gastric Carcinoma
- Recurrent Gastroesophageal Junction Adenocarcinoma
- Stage III Esophageal Cancer AJCC v7
- Stage III Gastric Cancer AJCC v7
- Stage IV Esophageal Cancer AJCC v7
- Stage IV Gastric Cancer AJCC v7
- Unresectable Esophageal Carcinoma
- Unresectable Gastric Carcinoma
- Unresectable Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Olaparib
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT03008278
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2023-06-30
- **Final completion:** 2025-08-13
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03008278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03008278, "Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03008278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*